An antibody cocktail from Regeneron has been approved by the FDA as the first treatment for Ebola, offering hope that the same approach could be used to combat COVID-19.

Regeneron’s antibody cocktail is the latest COVID-19 drug to receive Emergency Use Authorization in the US, becoming the first therapy of this kind to become available.

Lab experiments on Regeneron pharmaceuticals' REGN-COV2 -- a 2 recombinant monoclonal antibody cocktail -- showed that casirivamab had lost some of its neutralising activity against the South ...